Bruker Corporation (BRKR) recently announced the release of its latest innovative neuroscience research solution, the OptoVolt module, at the Neuroscience 2024 conference. The module uniquely addresses the challenges of voltage imaging by providing scanner technology. The latest release expands Bruker's Ultima multiphoton microscope platform with advanced neuroscience research capabilities. BRKR's Likely Stock Trend Following the News Subsequent to the news, the share price of BRKR moved south 1.6% to $65.9 ...

Bruker Corporation's (BRKR) growth is backed by strong sales within its X-Ray and Nano Analytics businesses. Within the PCI division, expanding customer demand for pre-clinical MRI systems is highly encouraging. Meanwhile, the impact of macroeconomic pressure and currency fluctuation is likely to hurt the company's operational results. In the past year, this Zacks Rank #3 (Hold) company's shares have gained 10.4% compared with the industry's 27.5% growth and the S&P 500 composite's 34.9% gain. This renowned ...

Dublin, Sept. 20, 2024 (GLOBE NEWSWIRE) -- The "Dermatology Diagnostic Devices Market (2024 Edition): Analysis by Type (Imaging Devices, Microscopes, Immunoassays, Molecular Diagnostics, Others), Application, End-user and Region: Insights and Forecast (2020-2030)" report has been added to ResearchAndMarkets.com's offering. This report provides a complete analysis of the Global Dermatology Diagnostic Devices industry for the historical period of 2020-2023, the estimates of 2024 and the forecast period of 202 ...

It has been about a month since the last earnings report for Bruker (BRKR) . Shares have added about 6.8% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is Bruker due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts. Bruker Q2 Earnings Meet Estimates, Revenues Rise Y/Y B ...

Bruker Corporation's (BRKR) BioSpin Group has been witnessing impressive growth in its end markets and the strategic buyout of Chemspeed is poised to expand its potential. Within BSI Nano, AI is driving significant growth in the semiconductor and metrology tools. The latest innovations and acquisitions in the CALID business uphold its robust growth prospects. Meanwhile, the impact of macroeconomic pressure and competitive challenges may hurt the company's operational results. In the past year, this Zacks Ra ...

Under a strategic partnership with Alamar Biosciences, Biognosys is a provider of choice of NULISA multiplex assay services for biopharma research The NULISAseq™ CNS Disease and Inflammation panels are now available for customers as a contract research service from Biognosys' high-end proteomics facility in Europe By offering the combination of NULISA affinity-based assays and TrueDiscovery® mass spectrometrybased plasma profiling with P2 Plasma Enrichment, Biognosys offers the industry's most comprehensive ...

Bruker Corporation (BRKR) recently announced the successful installation and acceptance of a 1.2 GHz Avance Nuclear Magnetic Resonance ("NMR") spectrometer at the Korea Basic Science Institute ("KBSI"). As the first 1.2 GHz NMR system in the Asia-Pacific region, the solution has set a new benchmark for molecular, cell biology and disease research by ultra-high field NMR. The latest development from the company arrives right before the 30 ICMRBS (International Conference on Magnetic Resonance in Biological S ...

Have you evaluated the performance of Bruker's (BRKR) international operations during the quarter that concluded in June 2024? Considering the extensive worldwide presence of this scientific equipment maker, analyzing the patterns in international revenues is crucial for understanding its financial resilience and potential for growth. In today's increasingly interconnected global economy, a company's ability to tap into international markets can be a pivotal factor in shaping its overall financial health an ...

Revenue Performance - Total revenue for Q2 2024 was $800.7 million, a 17.4% increase from $681.9 million in Q2 2023[7] - Product revenue reached $654.4 million in Q2 2024, up 16.9% from $559.6 million in Q2 2023[7] - Service and other revenue increased to $146.3 million in Q2 2024, compared to $122.3 million in Q2 2023, reflecting a 19.6% growth[7] - Total revenue for the six months ended June 30, 2024, reached $1,522.4 million, up 11.3% from $1,367.2 million in the prior year[29] - Revenue from the United States for the three months ended June 30, 2024, was $243.7 million, a 35.9% increase compared to $179.3 million in the same period of 2023[31] - Organic revenue for the three months ended June 30, 2024, increased by 7.4% excluding the effects of foreign exchange and acquisitions[142] - Organic revenue for the six months ended June 30, 2024, increased by 4.5% excluding the effects of foreign exchange and acquisitions[143] Profitability Metrics - Gross profit for Q2 2024 was $384.6 million, representing a gross margin of 48.0%, compared to 49.9% in Q2 2023[7] - Net income for Q2 2024 was $7.6 million, a significant decrease from $57.8 million in Q2 2023[9] - The company reported a total comprehensive loss of $28.9 million for Q2 2024, compared to a comprehensive income of $52.9 million in Q2 2023[10] - Operating income for the three months ended June 30, 2024, decreased to $48.1 million, a decline of 44.2% compared to $86.2 million in the same period in 2023[155] - Diluted earnings per share for the three months ended June 30, 2024, was $0.05, a decrease of $0.34 compared to $0.39 per share in the same period in 2023[145] - Gross profit margin decreased to 48.0% for the three months ended June 30, 2024, compared to 49.9% for the same period in 2023[144] Expenses and Investments - Research and development expenses for Q2 2024 were $92.2 million, up from $71.0 million in Q2 2023, indicating a 29.0% increase[7] - Total operating expenses increased by 32.3% to $336.5 million for the three months ended June 30, 2024, compared to $254.3 million in the same period in 2023[155] - Other charges, net for the six months ended June 30, 2024, included $21.6 million of acquisition-related charges, significantly up from $5.8 million in the same period in 2023[176] - The company expects to incur additional restructuring charges of $7.2 million through the remainder of 2024 as part of a global restructuring program[124] Balance Sheet Highlights - Total assets as of June 30, 2024, were $5,902.6 million, up from $4,249.9 million at the end of 2023[4] - Total liabilities increased to $4,078.1 million as of June 30, 2024, compared to $2,836.6 million at the end of 2023[5] - Total shareholders' equity attributable to Bruker Corporation was $1,807.0 million, an increase from $1,789.2 million at the end of the previous quarter[12] - Cash and cash equivalents decreased to $169.7 million from $488.3 million at the end of 2023[4] Acquisitions and Goodwill - The company completed various acquisitions in 2024, with total consideration transferred amounting to $1,613.0 million[37] - Goodwill allocated from acquisitions in 2024 was $876.1 million[37] - The company acquired NanoString Technologies, Inc. for approximately $392.6 million in cash, including the assumption of certain liabilities[38] - The Company incurred $7.2 million in acquisition-related expenses associated with the NanoString acquisition, primarily for legal and professional services[42] - The carrying amount of goodwill increased from $582.6 million at December 31, 2023, to $1,443.8 million at June 30, 2024[78] Cash Flow Analysis - Net cash provided by operating activities decreased to $22.9 million from $100.5 million year-over-year, a decline of about 77%[16] - Net cash used in investing activities rose sharply to $1,629.1 million from $134.2 million, reflecting increased capital expenditures and acquisitions[16] - Net cash provided by financing activities was $1,307.5 million for the six months ended June 30, 2024, mainly from proceeds from a revolving line of credit and long-term debt[188] Debt and Financing - The Company's total debt increased to $2,158.4 million as of June 30, 2024, up from $1,281.5 million at the end of 2023, reflecting a substantial rise in financial obligations[82] - The Company has a total of $900 million committed under the 2024 Amended and Restated Credit Agreement, with outstanding borrowings of $222.6 million as of June 30, 2024[83] - The Company entered into a term loan agreement providing for a CHF 150 million three-year term loan facility and a CHF 150 million five-year term loan facility[85] Tax and Compliance - The income tax provision for the three months ended June 30, 2024, was $16.1 million, representing an effective tax rate of 67.4%, compared to $19.9 million and 25.7% for the same period in 2023[108] - The effective tax rate increased primarily due to changes in jurisdictional mix and the impact of valuation allowance on capital loss carryforwards[108] - The Company had gross unrecognized tax benefits of approximately $69.4 million as of June 30, 2024, up from $58.5 million at the end of 2023[109] Shareholder Actions - Cash dividends declared and paid to common shareholders were $7.7 million, at a rate of $0.05 per share[12] - The Company approved a share repurchase program in May 2023, authorizing the purchase of up to $500.0 million of common stock, with $369.9 million remaining available as of June 30, 2024[113] - The Company completed a public offering in May 2024, issuing 6,000,000 shares at a price of $67.29 per share, resulting in net proceeds of approximately $403.0 million[116]

| --- | --- | --- | |----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------|-------| | | | | | Q2 2024 Earnings Presentation BRUKER CORPORATION (NASDAQ: BRKR) | | | | August 6, 2024 | | | | Frank H. Laukien, President & Chief Executive Officer Gerald Herman, Executive Vice President & Chief Financial Officer Joe Kostka, Associate Director, Investor Relations | | | BRUKER CORPORATION ...